Delcath Systems Inc (DCTH)
Delcath Systems Inc (DCTH) is a healthcare company specializing in innovative, proprietary targeted drug delivery systems for the treatment of cancer. Their flagship product, the HEPATIC CHEMOSAT Delivery System, is designed to deliver high doses of chemotherapy directly to the liver, aiming to improve treatment outcomes for hepatic cancers. The company focuses on developing and commercializing therapies that enhance the efficacy of chemotherapy while minimizing systemic side effects.
Company News
Delcath Systems (DCTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street is experiencing a subdued trading session, with all major indices showing minimal movement around midday in New York. The latest producer inflation data provided mixed signals ahead of the highly anticipated consumer inflation report on Wednesday. Fed Chair Jerome Powell reiterated his outlook that U.S. monetary policy will maintain i...
Are these penny stocks a buy before next year? The post Penny Stocks To Buy Now? 4 To Watch Before 2024 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
We've compiled a list of August investment picks that you may have missed. Some Seeking Alpha analysts are more discerning by nature. See their Buy recommendations here.
Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response and 100% Disease Control Rate. Median progression free survival currently is 22.4 months with all patients still alive as of last follow-up